| Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity WF Garcia-Beltran, EC Lam, KS Denis, AD Nitido, ZH Garcia, BM Hauser, ... Cell 184 (9), 2372-2383. e9, 2021 | 1629 | 2021 |
| mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant WF Garcia-Beltran, KJS Denis, A Hoelzemer, EC Lam, AD Nitido, ... Cell 185 (3), 457-466. e4, 2022 | 1121 | 2022 |
| Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression BP Fairfax, P Humburg, S Makino, V Naranbhai, D Wong, E Lau, L Jostins, ... Science 343 (6175), 1246949, 2014 | 855 | 2014 |
| Genital inflammation and the risk of HIV acquisition in women L Masson, JAS Passmore, LJ Liebenberg, L Werner, C Baxter, KB Arnold, ... Clinical Infectious Diseases 61 (2), 260-269, 2015 | 461 | 2015 |
| T-cell activation is an immune correlate of risk in BCG vaccinated infants HA Fletcher, MA Snowden, B Landry, W Rida, I Satti, SA Harris, ... Nature communications 7 (1), 11290, 2016 | 319 | 2016 |
| T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals V Naranbhai, A Nathan, C Kaseke, C Berrios, A Khatri, S Choi, MA Getz, ... Cell 185 (6), 1041-1051. e6, 2022 | 295 | 2022 |
| Genomic modulators of gene expression in human neutrophils V Naranbhai, BP Fairfax, S Makino, P Humburg, D Wong, E Ng, AVS Hill, ... Nature communications 6 (1), 7545, 2015 | 171 | 2015 |
| Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel V Naranbhai, SS Abdool Karim, M Altfeld, N Samsunder, R Durgiah, ... The Journal of infectious diseases 206 (7), 993-1001, 2012 | 166 | 2012 |
| Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells V Ramsuran, V Naranbhai, A Horowitz, Y Qi, MP Martin, Y Yuki, X Gao, ... Science 359 (6371), 86-90, 2018 | 159 | 2018 |
| Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy V Naranbhai, AVS Hill, SS Abdool Karim, K Naidoo, Q Abdool Karim, ... The Journal of infectious diseases 209 (4), 500-509, 2014 | 146 | 2014 |
| Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26. COV2. S COVID-19 vaccines V Naranbhai, WF Garcia-Beltran, CC Chang, C Berrios Mairena, ... The Journal of infectious diseases 225 (7), 1141-1150, 2022 | 140 | 2022 |
| A systematic review of definitions of extreme phenotypes of HIV control and progression D Gurdasani, L Iles, DG Dillon, EH Young, AD Olson, V Naranbhai, ... Aids 28 (2), 149-162, 2014 | 138 | 2014 |
| Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome CC Chang, AA Dorasamy, BI Gosnell, JH Elliott, T Spelman, S Omarjee, ... Aids 27 (13), 2089-2099, 2013 | 120 | 2013 |
| CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome S Kulkarni, A Lied, V Kulkarni, M Rucevic, MP Martin, V Walker-Sperling, ... Nature immunology 20 (7), 824-834, 2019 | 104 | 2019 |
| The association between the ratio of monocytes: lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life V Naranbhai, S Kim, H Fletcher, MF Cotton, A Violari, C Mitchell, ... BMC medicine 12, 1-6, 2014 | 104 | 2014 |
| Association of cutaneous immune-related adverse events with increased survival in patients treated with anti–programmed cell death 1 and anti–programmed cell death ligand 1 therapy K Tang, J Seo, BC Tiu, TK Le, V Pahalyants, NS Raval, PO Ugwu-Dike, ... JAMA dermatology 158 (2), 189-193, 2022 | 98 | 2022 |
| IFITM3 and Susceptibility to Respiratory Viral Infections in the Community TC Mills, A Rautanen, KS Elliott, T Parks, V Naranbhai, MM Ieven, ... The Journal of infectious diseases 209 (7), 1028-1031, 2014 | 89 | 2014 |
| Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer A Ravi, MD Hellmann, MB Arniella, M Holton, SS Freeman, V Naranbhai, ... Nature genetics 55 (5), 807-819, 2023 | 88 | 2023 |
| HLA-A* 03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study V Naranbhai, M Viard, M Dean, S Groha, DA Braun, C Labaki, SA Shukla, ... The Lancet Oncology 23 (1), 172-184, 2022 | 88 | 2022 |
| Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study V Naranbhai, CA Pernat, A Gavralidis, KJ St Denis, EC Lam, LM Spring, ... Journal of Clinical Oncology 40 (1), 12-23, 2022 | 86 | 2022 |